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The steroid module of the Athlete Biological Passport, the newest innovation in doping test-
ing, is currently being finalized for implementation. Several factors, other than doping, can
affect the longitudinal steroid profile. In this study, we investigated the effect of hormonal
contraceptives (HC) as well as the effect of three polymorphisms on female steroid profiles
in relation to doping controls. The study population consisted of 79 female elite athletes
between the ages of 18 and 45. HC were used by 32% of the subjects. A full urinary steroid
profile was obtained using World Anti-Doping Agency accredited methods. In addition all
subjects were genotyped for copy number variation of UGT2B17 and SNPs in UGT2B7 and
CYP17. Subjects using HC excreted 40% less epitestosterone as compared to non-users
(p=0.005) but showed no difference in testosterone excretion.When removing individuals
homozygous for the deletion in UGT2B17, the testosterone to epitestosterone (T/E) ratio
was 29% higher in the HC group (p=0.016). In agreement with previous findings in men,
copy number variation of UGT2B17 had significant effect on female urinary testosterone
excretion and therefore also the T/E ratio. Subjects homozygous for the T allele of CYP17
showed a lower urinary epitestosterone concentration than the other CYP17 genotypes. It
is of great importance that the athlete’s steroidal passport can compensate for all possible
normal variability in steroid profiles from women. Therefore, considering the large impact
of HC on female steroid profiles, we suggest that the use of HC should be a mandatory
question on the doping control form.
Keywords: doping in sports, hormonal contraceptives, genetic polymorphism, UGT2B17, CYP17, testosterone
doping, epitestosterone,T/E ratio
INTRODUCTION
Detection of doping with endogenous steroids, such as testos-
terone, has been and continues to be a challenge. To overcome
the problem of separating testosterone doping from endogenous
testosterone the ratio between the glucuronides of testosterone
and epitestosterone (T/E) is used. This T/E ratio was introduced in
doping tests with an authorized upper limit of 4. Interestingly, the
mean T/E ratio in Caucasian men is approximately 1 (1), whereas
in Asians, the mean ratio is considerably lower (2).
Glucuronidation of androgens by UDP-glucuronosyltransferases
(UGTs), i.e., phase II metabolism, is the major route for andro-
gen inactivation and excretion (3–6). UGT2B7 has been identified
as the enzyme responsible for epitestosterone conjugation (7, 8)
whereas testosterone is a poor substrate for this enzyme. Testos-
terone is mainly conjugated by UGT2B17 and to a minor extent by
UGT2B15. We have recently shown that testosterone glucuronida-
tion activity in the liver is significantly higher in men homozygous
for the insertion (ins/ins) of UGT2B17 than in women with the
same genotype (9).
We have also shown that the ethnic disparity in the T/E ratio is
strongly associated with a deletion polymorphism in the UGT2B17
gene (10). Individuals homozygous for this deletion (del/del) may
not reach a T/E ratio of 4 when doped with testosterone (11).
The deletion polymorphism is much more common in East Asian
populations as compared to Caucasians and Africans (12). There
are also individuals that have naturally high T/E ratios due to
decreased excretion of epitestosterone. In males, part of this low
epitestosterone excretion can be explained by a promoter polymor-
phism in the CYP17 gene (13), resulting in 64% higher T/E ratios
in men homozygous for the T allele (14). However, this polymor-
phism in relation to epitestosterone excretion has not been studied
in women.
Women show a greater individual variation in T/E ratio than
men due to concentrations near the detection limit for the method
of analysis as well as variations during the menstrual cycle (15).
Furthermore, the use of hormonal contraceptives (HC) has been
suggested to suppress the production of epitestosterone and thus
lead to an increase in the T/E ratio (16). In Sweden, a study has
shown that almost half of female elite athletes are using HC, a
frequency comparable to the general population of the same age
group (17). HC consist of a progesterone derivative (progesto-
gens) or a combination of a progestogen and synthetic or nat-
ural estrogen. Their main mechanism of action is inhibition of
ovulation. Both progesterone and estrogen are negative regula-
tors of the hypothalamic–pituitary–gonadal (HPG) axis, meaning
that an increase in these sex hormones results in a decrease in
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gonadotropin releasing hormone (GnRH), luteinizing hormone
(LH), and follicle stimulating hormone (FSH).
In 1994, it was shown that between-subject variation can
be removed in doping tests by using a series of measurements
obtained from the same individual (18). Six years later the con-
cept of the Athlete Biological Passport (ABP) was proposed. The
ABP uses a longitudinal approach where an individual’s previ-
ous results are logged and compared to the new results (19). The
hematological module of the ABP, used to detect blood doping, has
successfully been in use since 2009, while the module for steroid
doping is currently being finalized for implementation.
In this study, we investigated how three polymorphisms and
HC affect the steroid module of the ABP. Previously, there has
only been a few studies investigating the effect of genetic variation
and HC on female steroid profiles in relation to doping controls.
With the implementation of the steroid module of the ABP, the
sensitivity of doping tests has improved. The improved sensitivity
requires increased knowledge of how external factors influence the
steroid profile. More knowledge in this area is of great importance
for correct interpretation of female steroid profiles using the ABP
program.
MATERIALS AND METHODS
STUDY POPULATION
The study population included 57 female Olympic level athletes
who planned to participate in the up-coming summer or win-
ter Olympic Games (either Olympic team members or members
within the programs of the Swedish Olympic Committee). The
mean age of these subjects was 26 years with a range from 18 to
45. Information about HC use was collected and a written consent
was obtained from all subjects.
In addition, 22 elite female athletes, whom have given consent
for research on their blood and urine samples in their anony-
mous doping control forms, were included in the study. The
medical information on the doping control form was used to
gather information on hormonal contraceptive use.
Out of the 79 female athletes, 25 (32%) were using HC.
Two women were using progestogen only contraceptives (birth
control implant or desogestrel) while the remaining 23 were
using combined oral contraceptives. Sixteen subjects (68%
of those on HC) used progestogen dominated HC of the
second generation (levonorgestrel/ethinylestradiol or norethis-
terone/ethinylestradiol), while 8 subjects (32% of those on HC)
used estrogen dominated HC of the third and fourth generation
[norgestimate/ethinylestradiol, drospirenone/ethinylestradiol or
etonogestrel/ethinylestradiol (vaginal ring)].
MEASUREMENT OF URINARY STEROIDS
Urinary levels of testosterone, epitestosterone, androsterone
(A), etiocholanolone (Etio), 5α-androstan-3α,17β-diol (5α-diol),
and 5β-androstan-α,17βdiol (5β-diol) were determined follow-
ing the validated screening method of the World Anti-Doping
Agency (WADA) accredited doping laboratory. This method uses
gas chromatography–mass spectrometry (GC/MS) essentially as
described by Chung et al. (20), with minor modifications as pre-
viously described (21). All urinary values are expressed as the
unconjugated [typically <8% of glucuronide fraction (22)] plus
the glucuronide conjugated fraction. The effect of urine dilution
was adjusted for by normalizing the samples to a specific gravity
of 1.020.
COPY NUMBER ANALYSIS OF UGT2B17
DNA was extracted from the whole blood samples using QIAamp®
DNA Blood Mini kit (Qiagen). Triplicates of 10 ng/µL DNA-
samples were used to genotype for the UGT2B17 deletion poly-
morphism as we have previously described (14). This genotyp-
ing was achieved by using 7500 Fast Real-Time PCR systems
with albumin as internal control as described by Schaeffeler
et al. (23).
UGT2B7 AND CYP17 SNP ANALYSES
Genotyping assays from Applied Biosystems (Foster City, CA,
USA) were used to genotype for UGT2B7 H268Y and the T>C
substitution in the promoter region of CYP17A1. For CYP17 a
premade 20× genotyping mix was used (c_2852784_30) with 2×
TaqMan Universal PCR Master mix and 1µL DNA sample for a
total of 15µL. For the UGT2B7 genotyping a mix was prepared
with 2× TaqMan Universal PCR Master Mix, 0.6µM forward and
reverse primer (forward: AGC TGA CGT ATG GCT TAT TCG AA,
reverse: GGG TTT GGC AGG TTT GCA), 0.1µM of both probes
each containing a different allele (FAM-TTC AGT TTC CAT ATC
CAC TCT-MGB, VIC-TTC AGT TTC CTC ATC CAC TCT-MGB)
and 3µL DNA sample per 15µL reaction. Thermal cycling fol-
lowed a protocol for activation at 95°C for 10 min; 40 cycles of
denaturation at 96°C for 15 s, annealing/elongation at 60°C for
1 min, and lastly a hold at 4°C.
DATA EVALUATION
As most of the data were not normally distributed, the median with
range is given for all data, even in the few cases where the data
were normally distributed. Statistical analyses were performed
according to distribution with Student’s two-tailed t -test or the
Mann–Whitney U -test using GraphPad PRISM 6.0® (GraphPad,
San Diego, CA, USA).
RESULTS
INFLUENCE OF HORMONAL CONTRACEPTIVES
Female athletes using HC excreted epitestosterone at a significantly
lower rate [4.9 (range: 0.90–12.9) ng/mL] than females who did
not use HC [8.2 (range: 1.5–25.0) ng/mL, p= 0.0005, Figure 1A].
When removing the UGT2B17 del/del individuals (N = 6) the
T/E ratio was significantly higher in HC-users as compared to
non-users [0.9 (range: 0.39–3.4) and 0.7 (range: 0.08–2.8) ng/mL,
respectively, p= 0.016, Figure 1B]. There was no difference in uri-
nary testosterone levels in the HC group compared to the non-HC
group. There was also no difference in the A/Etio ratio nor the 5α-
diol/5β-diol ratio between the HC-users (0.80 and 0.23) and the
non-users (0.76 and 0.32). The A/E ratio was significantly higher
in the HC group (491, range: 59.4–994) compared to the non-HC
group (247, range: 63.1–589) as a consequence of the low epitestos-
terone levels in hormonal contraceptive users (p< 0.0001). The
data are presented in Table 1.
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FIGURE 1 | (A) Urinary epitestosterone concentration in elite female athletes not taking hormonal contraceptives (non-HC) as compared to those on HC. (B) T/E
ratio for the same athletes after removing the UGT2B17 del /del individuals (N =6).
POLYMORPHISMS IN UGT2B17, UGT2B7, AND CYP17 AND IMPACT ON
URINARY ANDROGENS
The allele frequencies of the genotyping analysis are shown in
Table 2. It should be noted that all of the subjects are Swedish;
however, some of them may have other ethnic descent than Cau-
casian. The genotyping results are in line with previous published
allele frequencies in Caucasians (14, 24).
Influence of the UGT2B17 deletion polymorphism
The UGT2B17 genotype had a large impact on the urinary testos-
terone levels and the T/E ratio. As there were only six del/del indi-
viduals, two in the non-HC group and four in the HC group the
urinary steroid levels and ratios were only calculated for the whole
group (Table 1). There were no significant differences between the
ins/del and the ins/ins group in testosterone levels or T/E ratio in
line with previous published results for female athletes (9). The 5α-
diol/5β-diol ratio was significantly higher in the del/del group as
compared to the combined ins/ins and ins/del group [0.99 (range:
0.45–1.8) and 0.32 (range: 0.06–0.64), respectively, p= 0.0018].
Influence of the UGT2B7 H268Y polymorphism
As a previous study showed that the YY genotype had higher glu-
curonidation activity than the HH and HY genotype, the study
subjects were divided into HH+HY and YY groups for increased
statistical power (25). There was however only threeYY individuals
in the HC group, which made it difficult to interpret the data in this
group and no p-values could be calculated. One of the YY individ-
uals also had a double deletion of the UGT2B17 gene, and had to be
excluded from the testosterone, T/E, and 5α-diol/5β-diol ratio cal-
culations. There was a tendency toward higher epitestosterone lev-
els in the YY group both for users and non-users of HC (Table 1).
Influence of the CYP17 promoter polymorphism
For increased statistical power the CC and CT group was com-
bined for the CYP17 genotyping analysis (Table 1). Among the
HC-users, the TT genotype was significantly associated with lower
epitestosterone levels [2.2 (range: 0.91–5.9)] compared to the
CT+CC genotype [5.6 (range: 1.6–12.9)] (p= 0.0036, Figure 2A;
Table 1). After removing the del/del individuals the HC-users
homozygous for the TT genotype also had significantly lower
testosterone levels as compared to the CT+CC genotypes [2.4
(range: 0.74–9.4) and 6.2 (range: 2.3–14.4), respectively, p= 0.017,
Figure 2B].
DISCUSSION
In this study, we show that use of HC has an impact on epitestos-
terone excretion, no effect on testosterone excretion and thus
significant effects on the T/E ratio. Urinary epitestosterone lev-
els were 40% lower in the HC-users when compared to non-users.
A 29% increase in T/E ratio could be discerned first after the indi-
viduals homozygous for the deletion polymorphism in UGT2B17
were excluded. Furthermore, our results confirm a strong link
between UGT2B17 deletion polymorphism and urinary testos-
terone levels in our female study group (9, 26). Here we show
for the first time a link between a SNP in the promoter region
of CYP17 and epitestosterone excretion in females. The subjects
homozygous for the T allele showed lower epitestosterone levels
than subjects with the CT and CC genotype.
Studies have shown that females display a larger intra-
individual variation in T/E as compared to men and that the
fluctuation of T/E in women varies throughout the menstrual cycle
(16, 27, 28). Mareck-Engelke et al. measured urinary steroid pro-
files in four women during two menstrual cycles with and without
oral contraceptives. They showed that the epitestosterone levels
were lower and varied less over the menstrual cycle in women using
HC. Without HC, the epitestosterone excretion seems to increase
during the last 2 weeks of the menstrual cycle, with a large inter-
individual variation (15). We were able to confirm the findings
of Mareck-Engelke’s that epitestosterone excretion decreases with
the application of HC. Our study population was too small to fur-
ther investigate the specific impact of estrogenic and progestogen
dominated contraceptives, but one might speculate that progesto-
gen dominated HC have a more profound effect on epitestosterone
excretion since progestogens are known to repress LH to a larger
extent than estrogens (29).
It has been shown that oral contraceptives reduce both ovar-
ian and adrenal androgen production (30–33). The studies
showed that serum testosterone, free testosterone, and serum
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Table 1 | Comparison between urinary steroid profiles for the non-HC
and HC group as well as urinary steroid profiles for different
genotypes.
All subjects Non-HC HC p-Value
N (%) 54 (68.4%) 25 (31.6%)
Testosterone (ng/mL) 4.1 (1.2–19.4) 4.5 (0.74–14.4) NS
Epitestosterone (ng/mL) 8.2 (1.5–25.0) 4.9 (0.9–12.9) 0.0005
T/E ratio 0.7 (0.08–2.8) 0.9 (0.39–3.4) 0.016
A/Etio ratio 0.76 (0.22–1.9) 0.80 (0.41–2.0) NS
5α-diol/5β-diol ratio 0.32 (0.06–1.0) 0.23 (0.08–0.68) NS
A/E ratio 247 (63.1–589) 491 (59.4–994) <0.0001
UGT2B17 Del/Del Ins/Del+ Ins/Ins p-Value
N (%) 6 (7.6%) 73 (92.4.0%)
Testosterone (ng/mL) 0.66 (0.46–1.5) 5.4 (0.74–19.4) <0.0001
Epitestosterone (ng/mL) 4.9 (1.8–21.5) 6.6 (1.2–25.0) NS
T/E ratio 0.15 (0.09–0.3) 0.8 (0.08–3.4) 0.0002
A/Etio ratio 1.1 (0.42–2.0) 0.77 (0.21–1.9) NS
5α-diol/5β-diol ratio 0.99 (0.45–1.8) 0.32 (0.06–1.0) 0.0018
A/E ratio 512 (179–994) 278 (59.4–849) NS
UGT2B7 no HC HH+H/Y YY p-Value
N (%) 38 (71.7%) 15 (28.3%)
Testosterone (ng/mL) 4.7 (1.2–13.7) 6.7 (2.1–19.4) NS
Epitestosterone (ng/mL) 6.9 (1.5–25.0) 11.2 (4.5–10.9) NS
T/E ratio 0.70 (0.08–2.8) 0.59 (0.11–1.6) NS
A/Etio ratio 0.78 (0.22–1.8) 0.77 (0.22–1.9) NS
5α-diol/5β-diol ratio 0.32 (0.09–1.0) 0.32 (0.06–0.64) NS
UGT2B7 HC HH+H/Y YY p-Value
N (%) 22 (88.0%) 3 (12.0%)
Testosterone (ng/mL) 4.3 (0.74–14.4) 11.1 (8.9–13.3) Too few
Epitestosterone (ng/mL) 3.9 (0.9–11.3) 6.2 (5.1–12.9) 0.059
T/E ratio 0.9 (0.39–3.4) 1.2 (0.7–1.6) Too few
A/Etio ratio 0.78 (0.41–1.5) 0.86 (0.78–2.0) NS
5α-diol/5β-diol ratio 0.26 (0.08–0.68) 0.23 (0.21–0.25) Too few
CYP17A1 non-HC TT CT+CC p-Value
N (%) 25 (47.2%) 28 (52.8%)
Testosterone (ng/mL) 6.6 (2.1–13.7) 4.7 (1.2–19.4) NS
Epitestosterone (ng/mL) 8.6 (2.6–22.8) 7.9 (1.5–25.0) NS
T/E ratio 0.70 (0.30–2.6) 0.6 (0.08–2.8) NS
A/Etio ratio 0.80 (0.22–1.4) 0.76 (0.32–1.9) NS
5α-diol/5β-diol ratio 0.32 (0.09–1.0) 0.34 (0.06–0.92) NS
CYP17A1 HC TT CT+CC p-Value
N (%) 10 (40.0%) 15 (60.0%)
Testosterone (ng/mL) 2.4 (0.74–9.4) 6.2 (2.3–14.4) 0.017
Epitestosterone (ng/mL) 2.2 (0.91–5.9) 5.6 (1.6–12.9) 0.0036
T/E ratio 0.99 (0.50–3.4) 0.80 (0.39–1.8) NS
A/Etio ratio 0.76 (0.44–1.2) 0.80 (0.41–2.0) NS
5α-diol/5β-diol ratio 0.38 (0.16–0.49) 0.21 (0.08–0.68) NS
The results are shown as median values with the range in parenthesis (all val-
ues are corrected for by specific gravity). NS, non-significant; A, androsterone;
Etio, etiocholanolone; 5α-diol, 5α-androstan-3α,17β-diol, 5β-diol, 5β-androstan-
α,17βdiol; E, epitestosterone.
Table 2 | Allele frequencies of the three investigated polymorphisms
shown as total number of athletes with the specific genotype and
percentage of the whole study group.
UGT2B17 Del/Del Ins/Del Ins/Ins
6 (8.3%) 40 (58.3%) 22 (33.3%)
UGT2B7 HH HY YY
16 (20.5%) 44 (56.4%) 18 (23.1%)
CYP17A1 TT CT CC
35 (44.9%) 31 (39.7.6%) 12 (15.4%)
dehydroepiandrosterone (DHEA) were significantly lower in HC-
users. None of these studies have, however, analyzed serum
epitestosterone concentrations. Unfortunately, we do not have
serum data from our study subjects to investigate changes in serum
concentrations. A possible explanation for the reduction of uri-
nary epitestosterone while testosterone excretion stays unchanged
is that 30% of epitestosterone is excreted unchanged (apart from
being conjugated with glucuronic acid) as compared to only ~1%
of testosterone (34). Thus, an equal change in (T/E) production
will result in a 30 times larger change in epitestosterone than
testosterone excretion.
The CYP17 enzyme mediates central activities and functions
in human steroidogenesis in the adrenal gland, ovaries, and testes
(35, 36). The CYP17 promoter polymorphism has been exten-
sively studied. The CC (A2) variant was hypothesized to create an
additional Sp1 site in the promoter and thereby increase the tran-
scription of this gene (13), however activity studies have not been
able to confirm this finding (37). The theory is, however, consistent
with our findings in this and previous work (14) where the C-allele
is associated with increased levels of epitestosterone. We were able
to confirm our previous finding in men (14) that the C-allele is
associated with significantly higher urinary epitestosterone con-
centrations. This was only significant among the HC-users. This
may be due to the large variation in epitestosterone levels during
the menstrual cycle in non-HC-users. If urine had been collected
on the same day of the menstrual cycle (preferably in the begin-
ning) the difference may also have been shown in the non-HC
group. However, during urine collection for doping tests, as in
this study, the status of the menstrual cycle will be an unknown
factor. The C-allele was also associated with higher testosterone
levels in HC-users. A better controlled study in a larger group of
females is needed to confirm these findings. Previous findings are
inconsistent with some studies supporting higher levels of andro-
gens, estrogens,and DHEA while others showed no difference (38).
This, and our previous work (14), is to our knowledge the first to
associate this polymorphism with steroid levels in urine.
The UGT2B7 enzyme is known to be the main catalyst of
epitestosterone conjugation (8). Androsterone and androstane-
diol are also known substrates for this enzyme. A polymorphism
H268Y has been described in this gene, resulting in an amino acid
change within the substrate binding site (39). The YY variant has
been shown to be associated with significantly higher levels of
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FIGURE 2 | (A) The urinary epitestosterone concentration for elite female athletes divided in CYP17 genotypes and HC use. The CC and CT genotypes were
combined to increase statistical power. (B) The urinary testosterone concentrations after removing the UGT2B17 del /del individuals.
androstanediol glucuronides in serum (25). We were unable to
find any associations with this polymorphism and urinary steroid
levels (Table 1). The impact of genetic polymorphisms on the
steroid profile must be carefully interpreted since the study group
is small and the variation caused by the menstrual cycle in the
non-HC-users is large.
In addition to T/E ratio, other steroid metabolite ratios (e.g.,
A/Etio, 5α-diol/5β-diol, and A/E) are often used as biomarkers in
the evaluation of a steroid profile. The ratio of A/Etio and 5α-
diol/5β-diol does not seem to be affected during HC application,
which is important for doping control purposes. However, the 5α-
diol/5β-diol ratio, an important marker for dihydrotestosterone
doping (40), is affected by the UGT2B17 deletion polymorphism
(12, 26, 41) as 5β-diol is mainly glucuronidated by UGT2B17
(8). We and others have reported that A/E ratio is a sensitive
marker for testosterone doping. The A/E ratio is, unlike the T/E
and 5α-diol/5β-diol ratio, unaffected by the UGT2B17 deletion
polymorphism (42, 43). This ratio is however markedly affected
by the use of HC. As this ratio as well as the T/E ratio is affected by
HC, we share Mareck-Engelke’s concern that there will be major
changes when starting or stopping the use of HCs.
The up-coming implementation of the steroidal passport will
improve sensitivity in doping tests for steroids. This sensitivity is
however, not limited to doping. Factors such as genetics or drugs
use, can also affect the measured biomarkers. Genetic and other
influences on the steroid profile have not been extensively stud-
ied in women. It is paramount that the athletic steroidal passport
program can compensate for all possible standard variability in
steroid profiles from women. In this study we show, for the first
time, that HC as well as polymorphisms in UGT2B17 and CYP17
affect the female steroid profile. We suggest including information
on HC use as a standard question on the doping control form for
urine tests. This information should include whether an athlete
recently started or stopped taking HC as well as the duration for
which she has taken the current brand.
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